Low-Risk Myelofibrosis Shows Evidence of Disease Progression
About 60% of patients with low-risk myelofibrosis showed evidence of disease progression during 4 years of follow-up.
Read More
Myelofibrosis
LOXL2 Identified as Therapeutic Target in PMF
Findings from a recent study suggest LOXL2 plays a critical role in the pathogenesis of primary myelofibrosis.
Read More
AIPSS-MF Plus Next-Generation Sequencing Refines Prognosis & Survival Estimates
Using NGS in prognostic assessments enhances myelofibrosis prognosis and survival estimates, representing a step toward personalized medicine in myelofibrosis.
Read More
Shear Wave Elastography Beneficial in Diagnosing Myelofibrosis
Shear wave elastography differentiates myelofibrosis from essential thrombocytopenia and polycythemia vera and may help diagnose myeloproliferative neoplasms.
Read More
Myeloid-Derived Suppressor Cells Associated With Progression
Myeloid-derived suppressor cells are increased in the circulation and in the spleen of patients with primary myelofibrosis and may be new therapeutic targets.
Read More
Sociodemographic Data Helps Estimate Prognosis in Myelofibrosis
The first study to compare national myelofibrosis outcomes with a large minority cohort illustrates links between age, gender, and ethnicity and worse survival.
Read More
Shear Wave Elastography Distinguishes Myelofibrosis From Other MPNs
Spleen and liver elastography can help diagnose myeloproliferative neoplasms and differentiate myelofibrosis from other myeloproliferative neoplasms.
Read More
Haploidentical, Related, Unrelated: Does Donor Type Impact HTC Outcomes?
Matched sibling donors aside, donor type was not associated with significant differences in overall survival in patients with myelofibrosis who underwent HCT.
Read More
Altered Serum Metabolites in Primary MF Present Opportunities for Antioxidant Therapy
Altered serum metabolites in primary MF present opportunities for antioxidant therapy, as patients with PMF have a different metabolic makeup.
Read More
Analyzing Thrombotic Risk Factors
Recent findings underscore the need for clinicians to stratify arterial and venous thrombosis risks separately in patients with myelofibrosis.
Read More
Triple-Negative Myelofibrosis Shows Aggressive Behavior, Poor Outcomes
Triple-negative myelofibrosis affects 6% of myelofibrosis patients and is marked by aggressive clinical behavior and poor outcomes.
Read More
Anti-T-Lymphocyte Globulin Improves Survival Post-AlloHCT in Patients With Myelofibrosis
Anti-T-lymphocyte globulin significantly reduced the risk of GvHD, relapse, or death by 48%, enhancing GRFS, especially in matched donor transplants.
Read More
Does Splenomegaly Impact Transplant Outcomes?
Splenomegaly did not significantly impact transplant outcomes in patients who underwent hematopoietic stem cell transplantation for myelofibrosis.
Read More
Mutations and Proliferative Pathways Drive Myelofibrosis Evolution
Myeloproliferative neoplasms (MPN) are marked by the overproduction of myeloid cells, driven by...
Read More